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Background: Tafenoquine (TQ) is an 8-aminoquinoline (8AQ) that has been tested in several Phase II and Phase III
clinical studies and is currently in late stage development as an anti-malarial prophylactic agent. NPC-1161B is a
promising 8AQ in late preclinical development. It has recently been reported that the 8AQ drug primaquine
requires metabolic activation by CYP 2D6 for efficacy in humans and in mice, highlighting the importance of
pharmacogenomics in the target population when administering primaquine. A logical follow-up study was to
determine whether CYP 2D activation is required for other compounds in the 8AQ structural class.
Methods: In the present study, the anti-malarial activities of NPC-1161B and TQ were assessed against luciferase
expressing Plasmodium berghei in CYP 2D knock-out mice in comparison with normal C57BL/6 mice (WT) and with
humanized/CYP 2D6 knock-in mice by monitoring luminescence with an in vivo imaging system. These experiments
were designed to determine the direct effects of CYP 2D metabolic activation on the anti-malarial efficacy of
NPC-1161B and TQ.
Results: NPC-1161B and TQ exhibited no anti-malarial activity in CYP 2D knock-out mice when dosed at their ED100
values (1 mg/kg and 3 mg/kg, respectively) established in WT mice. TQ anti-malarial activity was partially restored in
humanized/CYP 2D6 knock-in mice when tested at two times its ED100.
Conclusions: The results reported here strongly suggest that metabolism of NPC-1161B and TQ by the CYP 2D
enzyme class is essential for their anti-malarial activity. Furthermore, these results may provide a possible explan-
ation for therapeutic failures for patients who do not respond to 8AQ treatment for relapsing malaria. Because CYP
2D6 is highly polymorphic, variable expression of this enzyme in humans represents a significant pharmacogenomic
liability for 8AQs which require CYP 2D metabolic activation for efficacy, particularly for large-scale prophylaxis and
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Figure 1 8-aminoquinoline anti-malarial compounds NPC-1161B
and tafenoquine. Shown are the structures of the compounds
utilized in this study. The quinoline rings are numbered (2–8) for
reference.
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The 8-aminoquinoline (8AQ) class of anti-malarial com-
pounds is extremely important in the fight against mal-
aria, as this class of molecules is unique due to the
efficacy against relapsing forms of malaria [1,2]. This ac-
tivity is a result of the anti-hypnozoite activity of the
8AQ class [2,3]. This attribute along with gametocytoci-
dal activity of primaquine (PQ) and other 8AQs make
the class attractive for mass administration in efforts to-
wards malaria eradication [4].
Recent advances in understanding the mechanism of
action for the 8AQ drug PQ have been reported [5-7].
PQ is metabolized by several different CYP enzymes as
well as monoamine oxidases [5-10], however, the anti-
malarial activity of PQ is mediated through CYP 2D6-
dependent activation to phenolic metabolites [6,7]. These
metabolites are capable of redox cycling and generating
reactive oxygen species [10-14], which is likely responsible
for anti-malarial activity. The activity of PQ was shown to
be dependent on CYP 2D6 activation in mouse models
and a human clinical trial. The results reported by Pybus
et al. clearly demonstrated in a mouse CYP 2D knock-out
model that PQ was inactive against Plasmodium berghei
and that the anti-malarial activity was partially restored at
its ED100 dose in a humanized/CYP 2D6 knock-in mouse
strain [6]. Bennett et al. demonstrated an association be-
tween poor and intermediate CYP 2D6 metabolizer phe-
notypes and failure of PQ for radical cure of P. vivax in
two human subjects [15].
CYP 2D6 belongs to the cytochrome P450 super family
of enzymes that are responsible for a variety of metabolic
and biosynthetic processes [16]. Humans have several dif-
ferent hepatic CYP P450 enzymes that metabolize drugs
to include CYP 1A1, 1A2, 2A6, 2B6, 2C19, 2C9, 2D6, 2E1,
and 3A4. Each CYP isoform has different substrate prefer-
ences and rates of metabolism (for a review on the CYP
P450 super family see [16]). Of the hepatic CYP P450
enzymes, CYP 2D6 is estimated to make up only four per-
cent of the total human P450 liver content, yet it is esti-
mated to metabolize 20-25% of commonly used drugs.
Despite the importance of CYP 2D6 in drug metabolism,
the enzyme is highly polymorphic in various human popu-
lations with more than 74 alleles reported to date [17].
CYP 2D6 phenotypes can be classified into four groups:
poor metabolizers (PMs), intermediate metabolizers (IMs),
extensive metabolizers (EMs), and ultra-rapid metaboli-
zers (UMs). The frequency of PMs varies among popula-
tions and can have large interethnic differences with
estimates in the range of 0-19% in African populations,
0–4.8% in Asian populations, and 1.5-8.9% in Caucasian
populations (for a more detailed description of CYP 2D6
genotypes and PM frequencies see [18-20]). These genetic
and phenotypic differences contribute to significant differ-
ences in the metabolism of CYP 2D6 substrates.Previous studies with PQ indicated that CYP 2D6 me-
tabolism was required for anti-malarial activity [6] and it
remained unclear if other 8AQ compounds similarly re-
quire CYP 2D6 activation. For this purpose, the 8AQ
compounds NPC-1161B and tafenoquine (TQ) (Figure 1)
were chosen and tested using CYP 2D knock-out and
humanized/CYP 2D6 knock-in mice. The CYP 2D knock-
out mice have a deletion of the mouse CYP 2D gene
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capable of metabolizing CYP 2D6 substrates [21]. The hu-
manized/CYP 2D6 knock-in mice have the deletion of the
mouse CYP 2D gene cluster, which is replaced with a hu-
man CYP2D6 expression cassette [21]. Both NPC-1161B
and TQ are promising 8AQ molecules in development as
TQ has been tested in several Phase II and III clinical
studies [22-26] and is in late stage development as an
anti-malarial prophylactic agent. NPC-1161B is a promis-
ing 8AQ in late preclinical development. Both compounds
have an O-aryl substituent at the 5 position. In part, these
compounds were selected to determine whether this key
difference with respect to PQ might overcome/alter CYP
2D dependence for efficacy.Methods
Chemicals used
NPC-1161B was supplied by Dr. Larry Walker and Dr.
Dhammika Nanayakkara from the Center for Natural
Products Research, University of Mississippi, and TQ
was obtained from the Walter Reed Army Institute of
Research chemical repository.Plasmodium berghei sporozoites isolation, inoculation and
viability check
Plasmodium berghei sporozoites (luciferase expressing)
were obtained from laboratory-reared female Anopheles
stephensi and maintained at 18°C for 17 to 22 days after
feeding on malaria-infected Swiss CD-1/ICR mice. Saliv-
ary glands were extracted from malaria-infected mosqui-
toes and sporozoites obtained. Briefly, mosquitoes were
separated into abdomen and head/thorax. Heads and
thoraxes were triturated with a mortar and pestle and sus-
pended in medium RPMI 1640 containing 1% C57BL/6
mouse serum (Rockland Co, Gilbertsville, PA, USA). A
total of 50–80 heads with glands were placed into a 0.5 ml
Osaki tube on top of glass wool with enough dissection
media to cover the heads. The Osaki tube was kept on ice
until all mosquitoes had been dissected. Sporozoites iso-
lated from the same batch of mosquitoes were inoculated
into C57BL/6, 2D knock-out and 2D knock-out/2D6
knock-in C57BL/6 mice on the same day to control for
biological variability in sporozoite preparations. Each
mouse was inoculated intravenously in the tail vein with
approximately 10,000 sporozoites suspended in 0.1 ml vol-
ume on day 0.
To ensure that inoculated sporozoites were viable fol-
lowing the isolation procedure, they were stained with a
vital dye containing fluorescein diacetate (50 mg/ml in
acetone) and ethidium bromide (20 μg/ml in phosphate-
buffered saline; Sigma Chemical Co, St. Louis, MO,
USA) and counted in a haemocytometer. The viability of
sporozoites ranged from 90 to 100%.Animals
Male eight- to 12-week old C57BL/6, 2D knock-out and
2D knock-out/2D6 knock-in C57BL/6 mice (Taconic,
Hudson, NY, USA) were used. On arrival, the animals
were acclimated for seven days (quarantine). The ani-
mals were housed in a cage maintained in a room with a
temperature range of 64-79°F, 34-68% relative humidity
and a 12-hr light/dark cycles. Food and water were pro-
vided during quarantine and throughout the study. The
animals were fed a standard rodent maintenance diet.
All animal studies were performed under IACUC ap-
proved protocols. All animal use, care and handling was
performed in accordance with the current Guide for the
Care and Use of Laboratory Animals (1996).
Test compounds and administration
Compounds tested in these experiments were dosed
based on the body weight at the time of preparation of
the suspension solution. The suspension solution of oral
agents were prepared in 0.5% (w/v) hydroxyethyl cellulose
and 0.2% (0.5% HECT, v/v) Tween-80 in distilled water,
using homogenizer (PRO Scientific Inc, Monroe, CT,
USA) with 10 mm open-slotted generator to homogenize
drug powder mixture at 20,000-22,000 rpm for 5 min in
ice bath. A once-a-day, three consecutive day-treatment
regimen (−1, 0, 1 day) was used in all assessments. Drug
suspensions were transferred to a 20-ml bottle, drawn into
a 1-ml syringe, and delivered via intragastric feeder (18
gauge) to the designated recipient.
In vivo imaging system spectrum
All in vivo imaging system (IVIS) methods utilized have
been described previously [6]. Briefly NPC-1161B and
TQ were administered orally on days −1, 0 and 1 with
respect to sporozoite inoculation. At 24, 48 and 72 hr
post-sporozoite infection, all inoculated mice were tested
using the Xenogen IVIS-200 Spectrum (Caliper Life Sci-
ences, Hopkinton, MA, USA) IVIS instrument. Addition-
ally, blood-stage infections were measured by a flow
cytometry system (FC500 MPL, Beckman Coulter, Miami,
FL, USA). Positive and negative controls were used for the
IVIS calibration in each test. D-Luciferin potassium salt,
(Xenogen, California and Goldbio, St Louis, MO, USA),
the luciferase substrate, was intraperitoneally inoculated
into mice at a concentration of 200 mg/kg 15 min before
luminescence analysis. Three min post-luciferin adminis-
tration the mice were anesthetized with isoflurane. The
mice were then positioned ventral side up in the IVIS on
the 37°C platform. The mice continued to receive iso-
flurane through nose cone delivery. The camera expos-
ure time was 5 min for the 24, 48 and 72 hr time points
with f-stop = 1 and large binning setting. Photons emit-
ted from specific regions were quantified using Living
Image® 3.0 software.
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NPC-1161B and tafenoquine efficacy in CYP 2D knock-out
mice
In order to determine if NPC-1161B (Figure 1) requires
activation through CYP 2D metabolism, NPC-1161B was
tested at its ED100 value (1 mg/kg) in C57BL/6 mice in-
fected with luciferase expressing P. berghei. The IVIS lumi-
nescence results for NPC-1161B are shown in Figure 2A
and quantitated luminescence values from parasite burden
in Figure 2B. The 48-hr IVIS measurements indicate levelsWT
WT + 









Figure 2 Dissemination of malaria parasites in C57BL/6 wild-type (WT
and 72 hr post-inoculation with luciferase expressing Plasmodium ber
of various mouse strains 48 and 72 hr post-inoculation. The mice of each g
dicated. B. Quantitated luminescence signal for each group tested 48 andof P. berghei liver infection while the 72-hr measurements
correspond to systemic P. berghei infection. Of the five wild
type (WT) (C57BL/6) mice infected with sporozoites and
not treated with NPC-1161B, all five exhibited robust lumi-
nescence signal as indicated by the IVIS images at 48 and
72 hr (panel i). The 1161B-treated WT group exhibited no
luminescence signal at either 48 or 72 hr, indicating that
NPC-1161B prevented P. berghei infection in WT mice
(panel ii). Panel iii shows the results from CYP 2D knock-
out mice infected with P. berghei as an infection control.CYP 2D KO
CYP 2D6 KI








), CYP 2D knock-out, and humanized/CYP 2D6 knock-in mice 48
ghei in the absence or presence of NPC-1161B. A (i-v). IVIS images
roup tested are shown and the corresponding luminescence signal in-
72 hr post-inoculation.
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the five mice showed parasite burden/infection throughout
the experiment. When NPC-1161B was tested at its ED100
in mice containing a deletion of the nine mouse CYP 2D
genes (nearest mouse orthologue to human CYP 2D6),
there was comparable luminescence signal to the WT con-
trol P. berghei infected mice at both 48 and 72 hr (panel iv)
indicating that NPC-1161B was inactive in the CYP 2D
knock-out mice. To investigate the effect of re-introducing
a CYP 2D enzyme, NPC-1161B was tested at its ED100 in a











Figure 3 Dissemination of malaria parasites in C57BL/6 wild-type (WT
and 72 hr post-inoculation with luciferase expressing Plasmodium ber
of various mouse strains 48 and 72 hr post-inoculation. The mice of each g
indicated. B. Quantitated luminescence signal for each group tested 48 andhas been removed and replaced with the human CYP 2D6
gene and infected with P. berghei sporozoites (panel v). Of
the five mice tested, all five mice had similar luminescence
signals as compared to the WT control P. berghei-infected
mice not treated with any compound. These results indi-
cate that replacing the CYP 2D gene cluster with human
CYP 2D6 was not sufficient to fully restore the activity of
NPC-1161B.
Tafenoquine (Figure 1) was also tested in the CYP 2D
knock-out mouse model. IVIS results are shown in




3 mg/kg TQ 
CYP 2D KO
CYP 2D6 KI




), CYP 2D knock-out, and humanized/CYP 2D6 knock-in mice 48
ghei in the absence or presence of tafenoquine. A (i-v). IVIS images
roup tested are shown and the corresponding luminescence signal
72 hr post-inoculation.
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mice infected with P. berghei and panel ii shows the P.
berghei-infected WT mice treated with TQ at its ED100
(3 mg/kg). There was no luminescence signal at either
48 or 72 hr post -infection in five out of the five mice
treated, indicating that TQ prevented P. berghei infec-
tion. Panel iii shows P. berghei-infected CYP 2D knock-
out mice treated with TQ at its ED100 (3 mg/kg). Each
of the five mice showed robust luminescence indicating
that TQ was not metabolized to the active form of the
molecule required for anti-malarial activity when the
CYP 2D gene cluster was removed. When TQ was tested
in the humanized/CYP 2D6 knock-in mouse strain at its
ED100, five out of the five mice showed robust lumines-
cence (panel iv), indicating that replacing the CYP 2D
gene cluster with human CYP 2D6 was not sufficient to
fully restore the activity of TQ. To determine if this effect
could be compensated for, TQ was tested at two times its
ED100 in the humanized/CYP 2D6 knock-in mouse strain.
The results in panel v show that there was less lumines-
cence signal in all five mice at 48 hr (as compared to WT-
infected controls) and no detectable luminescence signal
at 72 hr post-inoculation.
The results in Figures 2 and 3 correspond to P. berghei
infection 48 and 72 hr post-inoculation. In order to de-
termine if the initial IVIS measurements translated to
systemic infection, blood stage parasite burden measure-
ments were made out to 31 days post-inoculation and
the results shown in Table 1. The mouse strains testedTable 1 Cure rates in C57BL/6 wild-type (WT), CYP 2D
knock-out, and humanized/CYP 2D6 knock-in mice 31
days post-inoculation with Plasmodium berghei in the
absence or presence of NPC-1161B and tafenoquine
NCP-1161B













2DKO/2D6KI 2 × ED100 4/5
A cure is indicated if there was no detectable parasite burden in blood
measurements after 31 days post-inoculation.along with the corresponding NPC-1161B/TQ doses
given are indicated. The results for NPC-1161B (panel i)
are consistent with those shown in Figure 2 in that five
out of five WT mice treated with NPC-1161B never devel-
oped P. berghei infection. All other NPC-1161B groups
were euthanized before day 22 due to blood stage parasite
burden.
Tafenoquine blood parasite burden results are shown
in Table 1 and are consistent with the IVIS results shown
in Figure 3. Five out of five WT mice treated with TQ had
no detectable parasite burden after 31 days, in comparison
to the WT infection control or the CYP 2D knock-out
mice treated with TQ. TQ was only active in the human-
ized/CYP 2D6 knock-in mice at two times its ED100. Four
out of five mice were cured in the two times ED100 group.
All other TQ groups were euthanized before day 22 due
to blood parasite burden. These results along with those
above for NPC-1161B illustrate that both TQ and NPC-
1161B are active in the presence of the CYP 2D gene clus-
ter. Activity was partially restored when the dose of TQ
was adjusted to account for differences between mouse
CYP 2D and human CYP 2D6 enzyme activity.
Conclusions
Here direct preclinical evidence is presented that the
8AQ compounds NPC-1161B and TQ require metabol-
ism by the CYP 2D enzyme class for activity. Human
CYP 2D6 is involved in the metabolism of 20-25% of
commonly used drugs on the market and is the most
polymorphic of all CYP P450 enzymes [18,20]. These
data demonstrate the critical role that CYP 2D enzymes
play in the metabolic activation of NPC-1161B and TQ
to the active form(s) of the molecules responsible for
anti-malarial activity.
As might be expected, there appear to be differences
between the mouse and human CYP 2D enzymes, as the
anti-malarial activity of NPC-1161B and TQ were not
restored in the CYP 2D knock-out/humanized/CYP 2D6
knock-in mice when tested at their respective ED100
(1 mg/kg and 3 mg/kg, respectively) values. In previous
studies, the anti-malarial activity of PQ was partially re-
stored when tested at its ED100 in the CYP 2D knock-
out/humanized/CYP 2D6 knock-in mice [6]. While both
NPC-1161B and TQ failed to achieve efficacy in CYP 2D
knock-out/humanized/CYP 2D6 knock-in mice when
tested at their corresponding ED100 values, anti-malarial
activity was restored in the CYP 2D knock-out/human-
ized/CYP 2D6 knock-in experiments when the dose of
TQ was doubled from its corresponding ED100 value
(3 mg/kg to 6 mg/kg; NPC-1161B was not tested at two
times its ED100 due to limited numbers of CYP 2D KO/
CYP2D6 KI mice). Additionally, despite NPC-1161B and
TQ belonging to the same structural class as PQ, there
is little information available on the metabolism of these
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uncertain if there are any other CYP enzymes capable of
metabolising NPC-1161B and TQ, however, under the
experimental conditions described above, the CYP 2D
family is of primary importance for anti-malarial activity
in mice and likely in humans. Further studies are re-
quired to understand the mechanism by which CYP 2D6
activates the NPC-1161B and TQ.
The lack of anti-malarial activity for TQ and NPC-
1161B when tested in the CYP 2D6 knock-in mice could
largely be attributed to intrinsic differences between the
two CYP 2D enzymes (human vs. murine) as several
reports have indicated differences in substrate metabol-
ism and tissue expression between orthologues [21,27].
Scheer et al. showed using the CYP 2D6 reporter sub-
strate bufuralol, only about a 53% recovery of bufuralol
1′-hydroxylase activity in microsomes generated from
livers of the humanized CYP 2D6 knock-in animals ver-
sus those from the wild-type [21]. The CYP 2D6 knock-
in mice have reduced enzymatic activity as compared to
the WT CYP 2D mice that is required for 8AQ activa-
tion. Interestingly, this information could be utilized for
the dose adjustment of 8AQs in humans that have re-
duced CYP 2D6 activity, as in some IM phenotypes as is
done with other CYP 2D6-dependent drugs such as the
anticancer drug tamoxifen [28]. This highlights the po-
tential necessity of pharmacogenomic-guided therapy,
with optimal dosing tailored for individual patients based
on their CYP 2D6 genotype. It seems that the differences
in mouse CYP 2D vs. human CYP 2D6 metabolism re-
quired for the anti-malarial activity of the 8AQs is more
pronounced for the longer half-life 5-O-aryl analogues
(TQ and NPC-1161B) as compared to PQ. TQ and NPC-
1161B were not tested at two times their ED100 values in
the CYP 2D knock-out mice because it is unlikely that any
dose adjustment in mice lacking any functional CYP 2D
enzyme(s) would result in restoration of activity as previ-
ously reported for PQ [6].
Taking the results presented above in context with
literature reports, it is reasonable to conclude several
things about NPC-1161B and TQ. 1). The anti-hypnozoite
activity of NPC-1161B and TQ is dependent on CYP 2D
activation. 2). Both NPC-1161B and TQ will likely fail for
either causal prophylaxis and/or treatment indications in
patients with CYP 2D6 genotypes resulting in the PM
phenotype and may require dose modification in some
patients with an IM phenotype. It is interesting to note
that at the TQ and NPC-1161B doses tested in the
knock-out experiments described above, no blood schi-
zonticidal activity was observed. It is unclear as to how/
if the previously reported slow intrinsic blood schizonti-
cidal activity of TQ and NPC-1161B [3,29,30] is linked
to CYP 2D6 metabolism. Further work is required in
order to determine if CYP 2D6 metabolism is requiredfor the blood schizonticidal activity of TQ and NPC-
1161B in humans and whether this blood schizonticidal
activity is sufficient to allow TQ and NPC-1161B to act
as prophylactic agents in the absence of CYP 2D6
activation. Despite these issues, the requirement for
CYP 2D6 activation for activity in the CYP 2D knock-
out mouse model sheds light on another controversial
issue that has surrounded the 8AQ class for decades:
resistance.
There have been numerous reports in the literature of
PQ failures that are associated with PQ resistance
[1,31,32]. This “resistance” refers to the inability of PQ
to clear the hypnozoite form of the Plasmodium parasite.
There has been confusion around the idea of PQ resist-
ance as there are many confounding factors associated
with the various reports, such as patient population, pa-
tient adherence, dosing regimen, and concurrent blood
schizonticidal therapy [1,33]. The requirement of CYP
2D6 activation for PQ activity is another factor that needs
to be taken into consideration when reporting PQ resist-
ance. Interestingly, the reported PQ failure rates seem to
align with CYP 2D6 polymorphic allelic frequencies for
the PM genotype [1] as individuals with this genotype will
likely fail PQ therapy [15]. This is not a likely coincidence
and calls into question the existence of PQ resistance and/
or Plasmodium resistance to the 8AQ class in general,
particularly since the results reported herein suggest that
8AQs likely have a similar mechanism(s) of anti-malarial
activity which is mediated through CYP 2D6 activation.
TQ and NPC-1161B do not have the wealth of clinical
data that exists for PQ, so the existence of TQ and NPC-
1161B treatment failures is more difficult to interpret. Be-
cause TQ and NPC-1161B require CYP 2D activation for
activity, rates of treatment/prophylactic failures would
likely be in line with those noted for PQ use for both com-
pounds when administered to humans. If insurmountable,
this would present a major pharmacogenomic liability for
the 8AQ class of anti-malarial compounds. New drugs
with anti-hypnozoite activity are desperately needed to
combat relapsing strains of malaria and future research
and development efforts should ensure the complete
dissociation between CYP 2D6 metabolism and anti-
hypnozoite activity of new potential anti-malarial agents.
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